3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
275
Lung Neoplasms
106
Adenocarcinoma of Lung
27
Mesothelioma, Malignant
22
Neoplasms
19
Neoplasm Metastasis
18
Breast Neoplasms
13
Brain Neoplasms
13
Mesothelioma
10
Head and Neck Neoplasms
10
Ovarian Neoplasms
8
Colorectal Neoplasms
8
Recurrence
7
Adenocarcinoma, Bronchiolo-Alveolar
7
Small Cell Lung Carcinoma
6
NSCLC
6
Adenocarcinoma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Meningeal Carcinomatosis
5
Carcinoma
5
Urinary Bladder Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Solitary Fibrous Tumor, Pleural
4
Sarcoma
4
Pancreatic Neoplasms
4
Non-small Cell Lung Cancer Metastatic
4
Laryngeal Diseases
4
Carcinoma, Transitional Cell
4
Uterine Neoplasms
3
Uterine Cervical Neoplasms
3
Interventions
vandetanib
2
Cisplatin
2
dalotuzumab
1
X-Rays
1
Tissue Plasminogen Activator
1
Receptors, Vascular Endothelial Growth Factor
1
Pemetrexed
1
Octreotide
1
Naproxen
1
Gemcitabine
1
Cdc25C phosphatase (211-221)
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pleural Effusion
×
Pemetrexed
×
Clear all
NCT00942825
2017-05-24
CBP08-02
CanBas Co. Ltd.
Phase 2
Completed
195 enrolled
8 charts